ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
The Lancet Oncology
Latest Publications
TOTAL DOCUMENTS
10168
(FIVE YEARS 2339)
H-INDEX
318
(FIVE YEARS 84)
Published By Elsevier
1470-2045
Latest Documents
Most Cited Documents
Contributed Authors
Related Sources
Related Keywords
Latest Documents
Most Cited Documents
Contributed Authors
Related Sources
Related Keywords
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(21)00718-x
◽
2022
◽
Author(s):
Howard P Safran
◽
Kathryn Winter
◽
David H Ilson
◽
Dennis Wigle
◽
Thomas DiPetrillo
◽
...
Keyword(s):
Oesophageal Adenocarcinoma
◽
Her2 Overexpression
◽
Phase 3
◽
Trimodality Treatment
Download Full-text
Clinical advances in PET–MRI for breast cancer
The Lancet Oncology
◽
10.1016/s1470-2045(21)00577-5
◽
2022
◽
Vol 23
(1)
◽
pp. e32-e43
Author(s):
Amy M Fowler
◽
Roberta M Strigel
Keyword(s):
Breast Cancer
◽
Clinical Advances
Download Full-text
Should brachytherapy be added to external beam radiotherapy for prostate cancer?
The Lancet Oncology
◽
10.1016/s1470-2045(21)00406-x
◽
2022
◽
Vol 23
(1)
◽
pp. 23-25
Author(s):
Alfonso Gomez-Iturriaga
◽
Mira Keyes
◽
Jarad Martin
◽
Daniel E Spratt
Keyword(s):
Prostate Cancer
◽
External Beam Radiotherapy
◽
External Beam
Download Full-text
Is non-invasive Cytosponge the holy grail for Barrett's neoplasia?
The Lancet Oncology
◽
10.1016/s1470-2045(21)00755-5
◽
2022
◽
Author(s):
Michael Vieth
◽
Markus F Neurath
Keyword(s):
Holy Grail
◽
Non Invasive
Download Full-text
Overcoming immunotherapy resistance in NSCLC
The Lancet Oncology
◽
10.1016/s1470-2045(21)00711-7
◽
2022
◽
Author(s):
Michael MacManus
◽
Fiona Hegi-Johnson
Download Full-text
Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot
The Lancet Oncology
◽
10.1016/s1470-2045(21)00667-7
◽
2022
◽
Author(s):
Nastazja Dagny Pilonis
◽
Sarah Killcoyne
◽
W Keith Tan
◽
Maria O'Donovan
◽
Shalini Malhotra
◽
...
Keyword(s):
Real World
◽
Cross Sectional Study
◽
Barrett’S Oesophagus
◽
Sectional Study
◽
Cross Sectional
◽
Barrett's Oesophagus
◽
Biomarker Panel
Download Full-text
Prioritising access to cancer drugs
The Lancet Oncology
◽
10.1016/s1470-2045(21)00641-0
◽
2022
◽
Vol 23
(1)
◽
pp. e1
Author(s):
Mitchell J Elliott
◽
Eitan Amir
◽
Sallie-Anne Pearson
◽
Michael B Barton
◽
Brooke E Wilson
Keyword(s):
Cancer Drugs
Download Full-text
Radiographic progression-free survival in the ACIS trial for prostate cancer
The Lancet Oncology
◽
10.1016/s1470-2045(21)00719-1
◽
2022
◽
Vol 23
(1)
◽
pp. e4
Author(s):
Ian F Tannock
◽
Christopher M Booth
◽
Bishal Gyawali
◽
Anthony M Joshua
Keyword(s):
Prostate Cancer
◽
Radiographic Progression
◽
Progression Free Survival
◽
Free Survival
Download Full-text
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(21)00693-8
◽
2022
◽
Author(s):
David Cella
◽
Robert J Motzer
◽
Cristina Suarez
◽
Steven I Blum
◽
Flavia Ejzykowicz
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Patient Reported Outcomes
◽
Advanced Renal Cell Carcinoma
◽
First Line
◽
Open Label
◽
Phase 3
◽
Patient Reported
Download Full-text
Correction to Lancet Oncol 2021; 22: 1518–29
The Lancet Oncology
◽
10.1016/s1470-2045(21)00700-2
◽
2022
◽
Vol 23
(1)
◽
pp. e16
Download Full-text
Load More ...
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close